Category: news

University of Sydney and CarboHyde join forces in groundbreaking collaboration to combat natural toxins

University of Sydney, a leading innovator in researching natural toxins and poisons, and CarboHyde, a renowned expert in developing therapeutic carbohydrates are proud to announce their strategic partnership in the fight against natural toxins. This groundbreaking collaboration aims to advance research, develop effective solutions, and raise awareness about the detrimental impact of natural toxins on human health.

The world faces a growing threat from natural toxins, which can be found in various forms, including harmful algal blooms, venomous organisms, and poisonous plants. These toxins pose significant challenges to public health, wildlife, and ecosystems, demanding immediate attention and collaborative efforts to mitigate their harmful effects.

By combining their unique expertise, University of Sydney, led by Greg Neely and CarboHyde will work hand in hand to develop innovative technologies and approaches for neutralizing natural toxins and developing antidotes against poisoning or for prevention. “Our joint efforts will not only enhance the scientific understanding of these toxins but also pave the way for effective preventive measures and responsive strategies” – said Joseph Toth, CEO of CarboHyde. “Natural toxins present a complex and multifaceted challenge, requiring interdisciplinary solutions. This collaboration allows us to leverage our respective strengths and resources to address this pressing issue collaboratively. Together, we aim to develop comprehensive strategies that safeguard public health.” he added. 

The partnership between the University of Sydney and CarboHyde signifies a milestone in the fight against natural toxins. By combining their research capabilities, technical expertise, and industry knowledge, these two partners are committed to making significant contributions to toxin detection, risk assessment, and effective mitigation strategies.

InnoGly COST Action Closing meeting

Tamas Sohajda represented us at the closing meeting of InnoGly a European COST Action aimed at facilitating networking and innovation of glycans in the field of cancer research, autophagy, immunity, and glycosaminoglycans. This was a fantastic experience and the start of several useful collaborations for the future.

Innovations in cyclodextrin-supported drug delivery

Tamas Sohajda, member of our scientific board talked today about innovations in cyclodextrin-based drug delivery at the Royal Society of Chemistry in London at an event dedicated to Innovations in Encapsulation.

Welcome Daniel!

Welcome dinner party for Daniel Bisericaru from Francesco Trotta‘s lab, who will work with us at CarboHyde for several months on novel drug delivery systems – nanosponges targeting different organs.

Welcome Daniel!

Novoxyne and CarboHyde explore together cyclodextrin-based methods to reprogram somatic cells

Dr. Atsou Ochi recently published his invention related to methods for reprogramming somatic cells into pluripotent stem cell-like cells. Such cells may express pluripotency-inducing genes, including Oct4, Nanog, and Sox2, without introducing exogenous genes, proteins, or chemicals. The discovery that the inhibition of mechanosensitive and stretch-activated ion channels in somatic cells specifically activates pluripotency-inducing factor genes inspired the cell reprogramming culture methods in which somatic cells were incubated with the inhibitor, GsMTX4, against mechanosensitive and stretch-activated ion channels, cultured on the soft hydrogel surface, or treated with cholesterol depletion substance, methyl-beta-cyclodextrin (MβCD). 

Described methods produce pluripotent stem cell-like cells and subsequently re-differentiated cells, which include adipocytes, osteocytes, and neuronal cells. Methods may be combined to increase the efficiency of somatic cell reprogramming. 

To take the next step in development, Novoxyne and CarboHyde started a multiple-staged collaboration project to assess the effects of various cyclodextrins as reprogramming agents of somatic cells, components of stem cell differentiation, and future tools in stem cell-based therapies. 

Novoxyne and Dr Ochi will focus on comparing the effects of different cyclodextrin derivatives on cell redifferentiation, while CarboHyde’s expertise will be used to select and customize this project’s best-working cyclodextrin derivatives.

“We have always had a deep interest in using carbohydrates in novel ways of biotechnology. In fact, two out of our in-house pipeline programs are developed in these directions. Our collaboration with Novoxyne is likely to become a strong third one in a field that holds both great promise and huge challenges in the future of pharmaceutics. I am sure that this collaboration will be mutually rewarding and may open novel insights in the application of cyclodextrins in biotechnology” said CarboHyde’s CEO József Tóth about this upcoming collaboration.

ABOUT CARBOHYDE

CarboHyde is a private preclinical pharmaceutical start-up specializing in developing carbohydrate-based APIs. Our team consists of a small group of seasoned scientists with over 50 years of cumulative experience in the field of carbohydrate chemistry, analysis and pharmaceutical development. The company’s core focus is neurodegenerative diseases, yet we also have other pre-clinical programs in various unmet medical indications. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) and other companies focusing on CMC and clinical development to make our drug development process efficient. CarboHyde’s management team has extensive experience in medicinal chemistry, marketing, and pharmaceutical development. In addition, CarboHyde is supported by experienced advisers, consultants, and carbohydrate veterans.

ABOUT NOVOXYNE Novoxyne is a research company founded by Atsuo Ochi dedicated to discovering cures to human diseases. We have developed therapeutic fusion proteins based on the checkpoint receptor ligands and cytokines. We have also developed a groundbreaking reprogramming technology that converts somatic cells to stem cells without gene transfection. Our reprogramming technology quickly makes the limitless number of stem cells from any somatic cells and stem cell therapy will become very accessible and safe. No gene transfection, no embryonic stem cell, and no purification of mesenchymal stem cell is necessary for our technology to prepare a large number of stem cells.

Nice to have you on board, Nina; good luck with your studies!

Fresh brains are always welcome at CarboHyde, thus we are particularly happy to host Nina Burduja student of Antonino Mazzaglia from Università degli Studi di Messina for 6 months. Nina’s project is to create #biodegradable#nanomaterials based on #cyclodextrin as molecular carriers for bio-delivery and chemo and bio species monitoring.

Nice to have you on board, Nina, good luck with your studies!
Milo Malanga, László Ragányi, Kristóf Felegyi, Mihaly Balint, Tamas Sohajda, Tamás Vargadi, Gergely Toth

Our advisory board member will give a presentation at the Innovations in encapsulation 2023 event in London

Tamas Sohajda is delighted to share his upcoming keynote at the Innovations in encapsulation 2023 event organized by The Formulation Science and Technology group (FSTG) of the Royal Society of Chemistry, Dr. Shashi Rudrangi and Dr. Cuross Bakhtiar, where he will talk about Innovations in cyclodextrin encapsulation and how we see the future of this field at CarboHyde.
This will be held on Thursday, 20th April 2023, at Burlington House, London, United Kingdom.

Dr. Tamás Sohajda, Member of the Scientific Advisory Board, CarboHyde, and Former CEO of CycloLab, Hungary. – Innovations in cyclodextrins encapsulation: possibilities and challenges. (This lecture will cover advancements in cyclodextrin encapsulation of pharmaceutical, nutraceuticals, and cosmetics)

See the program details here.

First Genegut meeting and Ireland/UK visits

Last week our CSO, Milo Malanga, had the privilege to attend the kick-off meeting of the GENEGUT consortia (a highly specialized, Horizon Europe team developing novel tools for the oral delivery of RNA to treat Crohn’s disease in Cork.

He also met the team of Mary McNamara (https://www.tudublin.ie/research/postgraduate-research/graduate-research-school/meet-the-team/marymcnamara.html) at Technological University Dublin to discuss expanding potential collaborations and visited the Astrazeneca site in Cambridge, UK.

We are grateful for all of your hospitality and look forward to developing fruitful relationships in 2023. 

Scientific collaboration with University of Turin

Our CSO, Milo Malanga PhD spent the last week at Università degli Studi di Torino in the lab of Francesco Trotta, supporting students in their chemistry visions and creating nanosponges together as well as delivering a scientific seminar on the uses of cyclodextrin in biotechnology. We will explore together the potential uses of the created compounds as novel drug delivery systems in the coming months. Next year CarboHyde will host students from the Trotta lab to continue the synthetic work and create new compounds supporting our collaborative R&D program.